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Results of treatment with concurrent radiotherapy 
and cisplatin-based chemotherapy for cancer of the uterine cervix 
– a preliminary assessment
Ma∏gorzata Rusiecka1, Beata Ziemba3, Jacek Dryl1, Katarzyna Bojarowska1, Beata S∏ocka2
A i m.  To compare the results of radiochemotherapy and radiotherapy in patients with cervical cancer.
M a t e r i a l  a n d  m e t h o d s.  Fifty three patients with locally advanced cervical cancer, undergoing combined radiochemo-
therapy (C) and a control group of 50 patients treated with irradiation only (R) entered the study
R e s u l t s.  All patients in group C treated with concurrent radiochemotherapy showed positive therapeutic effect – no cases
of stable disease nor progress. Complete remission (CR) was observed in more than half of the cases (54.72 %) directly after
treatment, as compared with group R – 19.64%. However, more than 70% of patients treated with combined therapy demon-
strated bone-marrow damages. Only 4 of these patients (7.55%) did not complete cytostatic treatment because of thrombo-
cytopoenia. Low thrombocyte count caused permanent exclusion of the patient from the chemotherapy schedule. Post-irradia-
tion side effects, such as proctitis, urocystis and enterocolitis posed another problem: combined radiochemotherapy increased
the percentage of patients with post-irradiation reactions, although the intensity of these reactions was neither increased
nor lenghtier.
C o n c l u s i o n.  Our results of combining irradiation with cisplatin-based chemotherapy treatment allow to reccomend this
schedule of therapy as a standard for locally advanced cervical cancer treatment.
Wst´pna ocena wyników leczenia raka szyjki macicy napromienianiem skojarzonym 
z chemioterapià opartà na cisplatynie
C e l.  Badanie podj´to w celu wykazania ró˝nicy w wynikach leczenia radiochemioterapià i radioterapià, oraz wskazania me-
tody skuteczniejszej w leczeniu raka szyjki macicy.
M a t e r i a ∏  i m e t o d a.  Badaniem obj´to 53 chore na p∏askonab∏onkowego raka szyjki macicy, poddane radiochemiotera-
pii w okresie od maja 2000 r. do czerwca 2001 r. z powodu nowotworu zaawansowanego miejscowo: stadia kliniczne od IB-2
do IVA – grupa C. Grup´ kontrolnà stanowi∏o 50 kobiet z rozpoznanym rakiem szyjki macicy, w stadiach zaawansowania
klinicznego od IB-1 do IVA, leczonych wy∏àcznie radioterapià w 1997 roku – grupa R. Obie grupy by∏y porównywalne
pod wzgl´dem wieku, warunków napromieniania, rodzaju brachyterapii. W grupie C znalaz∏o si´ wi´cej chorych z za-
awansowanym nowotworem (bulky, oraz przewaga liczebna wy˝szych stadiów klinicznych). W grupie tej zastosowano wle-
wy cisplatyny 1 raz w tygodniu w dawce 40 mg/ m2, lecz nie wi´cej ni˝ 70 mg na 1 wlew. Z powodu masywnego krwawienia
z dróg rodnych 6 chorych napromieniono metodà hiperfracji: 2 x 1,2 Gy z przerwà 8 h, aby nie stosowaç hipofrakcjonacji he-
mostatycznej.
W y n i k i.  U wszystkich chorych grupy C zaobserwowano pozytywny efekt terapii, w tym ponad 50% ca∏kowitych remisji. U po-
nad 70% kobiet stosowano sterydy z powodu leukopenii, a 4 chore nie otrzyma∏y pe∏nej chemioterapii – 6 kursów cisplatyny,
z powodu trombocytopenii, która wydaje si´ byç najwi´kszym problemem leczenia skojarzonego. IloÊç odczynów popro-
miennych wzros∏a, lecz nie wyd∏u˝y∏a si´ w czasie, ani nie osiàgn´∏a wi´kszego nat´˝enia.
Po d s u m o w a n i e.  Wczesne wyniki skojarzonego leczenia radiochemioterapià p∏askonab∏onkowego raka szyjki macicy sà
bardzo obiecujàce i rekomendujà powy˝szy schemat jako standard terapeutyczny w tym schorzeniu.
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Cancer of the uterine cervix still remains a frequent cau-
se of death of women in Poland. Unfortunately there has
been no evident increase in the five-year survival rate,
despite the progress of clinical diagnostic methods, impro-
vement of treatment methods and an increase in the ge-
neral standard of living [1].
Epidemiological data from the Lower-Silesian Can-
cer Registry indicate only a slight trend for decreased in-
cidence, i.e. 1-2% per year since 1997. In 1999 cancer of
the uterine cervix accounted for 6.8% of total cancer ca-
ses among women in Lower Silesia, and it was the third
most common tumour after cancer of the breast and the
lung. It was also the fourth most common cause of death
after cancer of the breast, the lung and the stomach. In
1998 the standarized death rate for cervical cancer was
7.2/100 000 women [2].
The global combined percentage of five-year survival
in 1998 was 65.4% for all clinical stages; among them I° –
85%, II° – 66%, III° – 39%, IV° – 11% [3]. In the Lower
Silesia this percentage was lower – 55% [2].
The unsatisfactory results of treatment have provo-
ked a search for more efficient therapy schedules, particu-
larly for patients with locally advanced cancer [4-6]. In
25% of these cases the disease had spread and distant
metastases could be found. [7, 8]. Recently it has been in-
dicated that the application of chemoradiotherapy, i.e.
combined treatment with ionizing irradiation and cytosta-
tic drugs is the optimal solution for the majority of pa-
tients with cancer of the uterine cervix. In such a combina-
tion the cytostatic drug is both a radio-sensitizer and
a systemic supplement for radiation, which is generally lo-
cal in application [9, 10]. Cisplatin seems to be the
most effective drug among the numerous cytostatics te-
sted during the preliminary phase of clinical investiga-
tions.
Material
Between May 2000 and June 2001 53 patients with invasi-
ve squamous cell carcinoma of the uterine cervix (group
C of concurrent approach) underwent radiochemothe-
rapy in the Clinic of Oncological Gynaecology at the De-
partment of Oncology of the Medical Academy of Wro-
c∏aw.
50 patients treated with ionising energy only (i.e. ra-
dically irradiated) in the same Clinic in 1997 served as
the control R group.
Both groups did not differ as to mean age (48 yrs
in group C; 51 yrs in group R). Identical radiotherapy
methods based on calculated doses to the radiated area
were used for both groups. In both groups stage IVA
cervical carcinoma was determined by cystoscopy, and
pathomorphologically confirmed as infiltration of the
mucosa of bladder (to a maximum diameter of 2.0 cm). In
group R the majority (64 %) of patients were in stage
I and II of cervical carcinoma (according to FIGO), hi-
gher stages (III and IV) dominated in group C (54.7%),
(Table I).
Table I. Stage of advancement of cervical carcinoma acc.
to FIGO in group R (radiotherapy alone)
and group C (concurrent radiochemotherapy)
FIGO No of cases % in groups
stage R C R C
1 B 11 4 22.00 7.55
2 A 3 2 6.00 3.77
2 B 17 18 34.00 33.96
2 A 1 2.00
3 B 14 28 28.00 52.83
4 A 4 1 8.00 1.89
All 50 53 100.00 100.00
The groups differed only as to the T character in
clinical stage I. Among patients in clinical stage IB, radio-
chemotherapy (group C) was applied to those with "bulky"
tumour (stage IB2 according to FIGO). In group R (tre-
ated with radiation only) there were patients with stage
IB2 with high tumour mass (2 patients) as well as IB1 – 8
patients with cervical diameter at a lower 4 cm. Six pa-
tients of group C were treated (because of intensive vagi-
nal haemorrhage) with hyperfractionational radiation (2
fractions daily, each with 1.2 Gy at 8 hr intervals).
Before starting the concurrent treatment the weight
and height of the patients was determined, because the
cytostatic doses depended on the body area. The patients
underwent careful examination, and those suffering from
diseases limiting fluid intake (necessarily increased during
cisplatin treatment) were excluded from the study. None
of the patients suffered from major circulatory diseases,
a number of them reported mild arterial hypertension.
During chemotherapy treatment cisplatin was applied in
a dose of 40 mg/1 m2 of body area, the maximum dose not
exceeding 70 mg per course. Body surface area varied
between 1.4 and 2.0 m2; maximum weight was 91 kg. Wo-
men of body surface >1.75 m2 received the maximum
dose (70 mg).
Methods
R a d i o t h e r a p y
Megavoltaged teletherapy and brachytherapy with "after-load"
was applied. In a period of 5 weeks (from Monday to Friday) the
patients were irradiated with a fraction dose (Df) = 1.8-2.0 Gy to
the total dose (Dc) = 46.8-50.4 Gy in reference point and, in the
case of hyperfractionation, Df = 1.2 Gy (2.4 Gy/24 hrs), Dc =
46.8-50.4 Gy/ in reference point over 4 weeks. Brachytherapy was
applied after observing regression of tumor infiltration. In case
of stage IB1 in group R, from the onset of treatment brachythe-
rapy was carried out with external beams (beginning the applica-
tions from the probe to the cavity of the uterus). For all the re-
maining patients (both C and R groups) brachytherapy was ini-
tiated in the fourth and sixth week of therapy. In all cases the
Selectron LDR/MDR (given in 4 fractions Dc = 6200-6400 cGy
in reference isodose) was used.
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C h e m o t h e r a p y
Cisplatin-based chemotherapy at a dose of 40 mg/m2 of body
area (up to a maximum dose of 70 mg) was given in one infusion.
Administration took place once a week (on Sundays, between
periods of radiotherapy). A maximum of 6 such courses were ap-
plied.
Chemotherapy was applied only if the following were met:
HB equal or higher than 10.0%, leucocyte count – over 3000,
granulocyte count – over 1500, thrombocyte count – over 100
000. During therapy we monitored the function of bone-marrow,
the liver and the kidneys. Kidney function was monitored acc. to
the urea and creatinine level and with the aid of fluid balance
during treatments.
In a number of cases chemotherapy was administerd despi-
te a leucocyte count of 2500, providing the granulocyte count was
above 1500. In such cases vitamin B6, Leucogen or steroids were
administered. One patient (admitted from a different hospital
after genital haemorrhage) was given two units of packed red
cells, and treatment was started at 9.7 g% HB. On the second
day (after cytostatic medication) one unit of packed red cells
was given. In this case, radiotherapy was considered to be the
only possible form of treatment – locally advanced, haemorrha-
ging cervical cancer.
The therapeutic effect was evaluated directly after treat-
ment using the following criteria: CR – total regression of tumor
infiltration confirmed by clinical examination; PR – regression of
over 50% of original magnitude; SD – no improvement (state sa-
me as before treatment); P – progression of neoplastic growth as
compared to the state before treatment.
Toxicity of treatment was estimated according to the WHO
scale [NEW Common Toxicity Criteria (CTC), Version 2.0,
NCIC CTG MA/BMS CA 151-007, Revised March, 1998]
Results
In the group treated exclusively with irradiation (R) the
ratio of patients in class CR was only 0.4 that in class PR,
and in ca. 1/3 of patients the early clinical assessment
showed therapeutic failure, manifested by progression of
the disease in 12 women in stage IIIb.
The scheduled radiotherapy dose was applied in all
cases. Because of anemia nine patients underwent blood
tranfusion and erythocyte transfusion, however leukopo-
enia requiring steroid treatment was not observed.
Among the patients in the PR class 6 (12%) had
acute post-irradiation reactions of 2nd degree acc. the
WHO scale (urocystitis, enterocolitis radiogenes).
All patients in group C showed a positive therapeu-
tic effect – in no case did the disease progress. Directly
after treatment complete remission of disease (CR) was
observed in more than half of the patients (29 pts –
54.72%), and in those remaining (24 pts – 45.28%) partial
remission was observed.
However in more than 70% of patients the bone-
-marrow function was impaired, sometimes affecting all
cell lineages. These 38 patients (71.7%) suffered from
leukopoenia (including granulocytopoenia). Both in class
CR (22 pts) and in class PR (16 pts). In 5 cases (9.43%)
thrombocytopoenia (2 – CR, 3 – PR) was observed.
Because of symptoms of hematologic toxicity in 4
patients (7.55%) complete cytostatic tratement was not
applied: one woman received only 2, and three women
only 5 cisplatin-based courses. In 21 cases (39.62%) en-
corton treatment was necessary; (13 CR; 8 PR). Neupo-
gen was given to 5 patients (9.43%- 1 CR; 4 PR). Eight
patients (15.09%) received packed red cell transfusions
and 3 (5.66%) also required thrombocyte supplementa-
tion.
The radiotherapy regime was completed in all pa-
tients, however in 24 (45.28%) the acute post-radiation re-
action (urocystitis, enterocolitis radiogenes) – classified as
2nd degree occurred. This reaction was successfully treated
during radiochemotherapy.
Discussion /Summary – conclusions
In recent years many medical centers have undertaken
trials of concurrent radiochemotherapy for cancer of the
uterine cervix, using such cytostatics as 5-flurouracyl, to-
potecan, gemcytabine, hydroxyurea either together with
cisplatin or as a monotherapy, and their results have indi-
cated a positive therapeutic effect [11-13]. However, one
may find other reports questioning the advantages of
such treatment [14]. Because such therapeutic schemes
are fairly new, there are no publications in Polish literatu-
re regarding the immediate results of concurrent chemo-
radiation for cervical cancer, nor the safety of this treat-
ment. There is also no data concerning the long-term ef-
fect of such treatment.
Our results appear to be similar to the results re-
ported by other authors [7, 15, 16]. It is worth emphasi-
zing, that in the group of patients undergoing radio-che-
motherapy we observed improvement in every single case,
while in four cases we have even observed spectacular
results – a 10-12 cm tumour decreased to 3.0-4.5 cm after
therapy. Definitely better therapeutic results were obse-
rved after radio-chemotherapy, compared to radiothera-
py alone, despite a greater ratio of advanced cases.
Concurrent radiochemical therapy was generally
well-tolerated by patients, but some undesirable symp-
toms were observed. Our study confirms hematologic ef-
fects of cisplatin-based chemotherapy together with ioni-
zing radiation, reported by others [17].
The complications caused by anemia [18] and leuko-
poenia are not a serious argument against the use of che-
mo-radiotherapy as it is possible to provide compensato-
ry treatment. The one serious problem – low platelet co-
unt – may bring on exclusion from completeing the 6
courses, however such was the case only for 4 patients
(7.5%), and three of them (5.7%) managed as many as 5
courses. Only in 1 case (1.9%) traetment had to be di-
scontinued after 2 courses.
Table II. Comparison of treatment results after radiotherapy (group R) 
and radiotherapy + chemotherapy (group C)
Result No of cases % in groups
of therapy R C R C
CR 11 29 19.64 54.72
PR 27 24 48.21 45.28
P 12 32.14
All 50 53 100.00 100.00
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Radiotherapy did not have to be suspended. Only
a 10 day-pause (and in a sole case – a 21day pause) was
necessary in patients with a low thrombocyte count (one
patient after the first week of radiotherapy + 2 courses of
cisplatin, two patients after teletherapy, and before bra-
chytherapy).
Given the high efficacy of the treatment, it is worth
considering the possibility of giving the calculated dose
(i.e. over 70 mg) to patients with body surface area over
1.75 m2. The maximal dose for our patients would reach
some 80 mg. At present it appears that the 70 mg dose has
not been exceeded by any other study group.
There were problems concerning post-irradiation
reactions within the digestive system and urinary tract.
The application of cytostatics increased the number of
patients with post-radiational diarrhoea and inflamma-
tion of the urinary tract, but the intensity of these reac-
tions were neither increased nor long-lasting.
Such reactions may have been influenced by the ap-
plication of brachytherapy only after a 30 Gy dose at the
reference point, i.e. only after 4 cisplatin infusions. In
the case of treatment with ionizing radiation alone (main-
ly for the patients in stage IB1) brachytherapy was often
initiated in the second week of external beam irradia-
tion. In those cases a local dose increase of PTV occurred
already at the onset of teletherapy, but not at its second
phase (or after external beam irradiation), as was the ca-
se in the concurrent approach.
In summary our results suggest that programmes
combining radiotherapy treatment with cisplatin-based
chemotherapy can be recommended as an optimal stan-
dard for cervical cancer treatment.
Ma∏gorzata Rusiecka M.D. Ph.D.
Department of Oncology 
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